Is Upstream Bio, Inc. (UPB) overvalued? · rev $2.4M
Upstream Bio, Inc. (UPB) is a biotechnology company listed on US.
This page asks whether Upstream Bio, Inc. (UPB) looks expensive on cached numbers — not a short thesis.
Latest reported UPB revenue for 2024-12-31 was $2.4M. Net income was -$62.8M. Revenue was down 0.4% from 2023-12-31 to 2024-12-31. UPB currently screens at market cap $407.3M.
UPB currently screens at market cap $407.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next UPB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the UPB stock page for the full model, not this heading.
Not investment advice.